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Abstract
Introduction The objective was to study immune regulation in a
mouse model of rheumatoid arthritis that exhibits considerable
heterogeneity of disease activity.
Methods T-cell receptor transgenic mice, in which nearly all
CD4+ T cells recognize a single peptide of type II collagen, were
immunized with collagen and observed for development of
arthritis for 4 weeks. At 28 days post-immunization, splenocytes
were analyzed by flow cytometry and in vitro assays for markers
of immune activation and regulation.
Results Disease severities ranging from 0 to 12 (on a 12-point
scale) were observed. Among splenic lymphocyte populations,
only the CD5+ B-cell subset displayed a decrease in relative
numbers as arthritis severity increased. Splenic CD5+ B cells
expressed higher levels of Fas ligand (FasL) than did CD4+ T
cells or CD5- B cells in all mice, and antigen-dependent T-cell
death correlated with higher levels of CD5+ B cells in
cocultures. Ratios of interleukin (IL)-17 to interferon-gamma
production were higher in antigen-driven cultures of splenocytes
from severely arthritic mice compared to mildly or nonarthritic
mice. A correlation was established between the reduced
production of IL-17 in antigen-driven T-cell/B-cell cocultures
and FasL, but not IL-10. Confirmation of the direct killing effect
of B cells on T cells was demonstrated using an antigen-specific
T hybridoma cell line.
Conclusions Reduced numbers of splenic FasL+ CD5+ B cells
correlated with increasing arthritis severity and decreased T-cell
death in a T-cell receptor transgenic mouse model of collagen-
induced arthritis. These 'killer' B cells may provide a novel
mechanism for inducing T-cell death as a treatment for arthritis.
Introduction
Rheumatoid arthritis (RA) is a destructive inflammatory dis-
ease of the joints, is associated with genetic and environmen-
tal risk factors, and shows strong evidence of being mediated
by cells of the immune system [1,2]. The most important
genetic risk factor for RA is the inheritance of polymorphic
major histocompatibility complex (MHC) class II alleles con-
taining the 'shared epitope', which occurs in approximately
40% of the healthy Caucasian population but in approximately
70% of RA patients within that group [1,3]. The critical role of
MHC class II in the presentation of antigens to CD4+ T helper
(Th) lymphocytes has long implicated Th cells as effector cells
in RA [4,5]. Evidence from animal models of arthritis has
shown that Th cells, particularly Th17 cells, which produce the
proinflammatory cytokine interleukin (IL)-17, play an important
role in mediating arthritis [6-9]. The role of Th17 cells in human
RA is less established, but it is known that IL-17 can act
directly on fibroblast-like synoviocytes, macrophages, and
osteoclasts to induce proinflammatory mediators implicated in
RA synovial damage [10-12]. Thus, regulation of Th17 cells
has become an attractive target for treatment of RA.
One level of control of Th cells is at the induction phase, which
is regulated by direct interaction of naïve Th cells with profes-
sional antigen-presenting cells (APCs), including dendritic
cells, activated macrophages, and activated B lymphocytes.Page 1 of 12
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APCs and T cells drives Th cells to become Th1, Th2, regula-
tory T (Treg), or Th17 cells that produce the characteristic
cytokines: interferon-gamma (IFNγ), IL-4, IL-10, or IL-17,
respectively [13,14]. In mice, the presence of IL-6 and low lev-
els of transforming growth factor-beta at the time of T-cell acti-
vation drives Th17 cell differentiation, whereas the presence of
other Th cell cytokines such as IL-4 and IFNγ inhibits Th17 cell
induction [15,16]. Interactions between co-stimulatory or reg-
ulatory cell surface molecules on APCs and their counter-
receptors on T cells may also play an important role in Th cell
cytokine production. Manipulating the cytokine microenvirone-
ment and/or interactions between APCs and Th cells may
have profound effects on Th cell activation and disease
outcome.
One level of control of Th cell activity involves the induction of
Th cell death (apoptosis), which can be mediated through
intrinsic or extrinsic pathways. The best studied extrinsic path-
way of T-cell death involves ligation of the Fas death receptor
(CD95) by Fas ligand (FasL, CD95L, or CD178) [17] and is
dependent on activation of the target cell. Deficiencies in Fas
or FasL lead to severe lymphoproliferative disease in mice,
manifesting in a lupus-like condition [18]. Conversely, adop-
tive transfer of genetically engineered APCs with forced
expression of FasL was shown to prevent arthritis in an animal
model [19]. Previous studies have shown that FasL can be
naturally expressed by mouse or human B cells and can lead
to induction of Th cell apoptosis and control of inflammation
[20-22]. In particular, the small population of CD5+ B cells in
the spleen has been shown to be constitutively positive for
FasL and were potent mediators of T-cell apoptosis [23]. FasL
expression on CD5+ B cells was upregulated by IL-4 and IL-
10, and previous studies have shown that IL-10 can be pro-
duced by CD5+ B cells [23-25]. These results led us to
hypothesize that CD5+ B cells could play a role in regulating
arthritis through interactions with arthritogenic T cells.
In the present study, we have used a T-cell receptor (TCR)
transgenic (Tg) mouse model in which immunization with type
II collagen (cII) can potentially stimulate all of the Th cells
within the mouse. Initial results indicated that a group of these
immunized cII TCR Tg mice developed severe arthritis with a
rapid onset whereas other mice developed moderate, mild, or
even no arthritis over a 28-day time period. Analysis of the
splenic lymphocytes in these mice revealed that severely
arthritic mice had relatively fewer CD5+ B cells than mildly or
moderately arthritic mice. FasL expression was highest on
CD5+ B cells compared with other lymphocyte subsets, but
the level of expression on individual cells was not correlated to
disease activity. Importantly, increased T-cell apoptosis corre-
lated with the relative number of FasL+ B cells in cocultures,
and differences in IL-17 and IFNγ production patterns were
evident after neutralizing FasL. A direct killing effect of B cells
on a T-cell line specific for an arthritogenic autoantigen was
also demonstrated. This is the first evidence that killer B cells
may play a role in regulating arthritogenic T cells.
Materials and methods
Mice, immunizations, and arthritis measurement
Wild-type DBA/1LacJ mice and a breeding pair of TCR Tg
(D1Lac.Cg-Tg(TCRa,TCRb)24Efro/J) mice were purchased
from The Jackson Laboratory (Bar Harbor, ME, USA). Breed-
ing was performed in the facilities of the Unit for Laboratory
Animal Medicine of the University of Michigan Medical School,
and all procedures were approved by the Institutional Animal
Care and Use Committee. Transgene expression was con-
firmed in all offspring by polymerase chain reaction analysis of
tail biopsies. The TCR transgene is reported to be specific for
an immunodominant peptide of cII (cII260-267) when bound to
MHC class II I-Aq molecules (DBA/1 background) [26].
C57BL/6- [Tg] DR-4- [KQ]ABB (human class II MHC
DRB1*0401 [DR4] Tg) mice were purchased from Taconic
(Hudson, NY, USA). Female mice were immunized at the base
of the tail with 0.1 mg of freshly solubilized type II chicken col-
lagen (Chondrex, Redmond, WA, USA) emulsified in complete
Freund's adjuvant (CFA) (Chondrex). Paw swelling was
assessed every 3 or 4 days following immunization and was
scored on a 4-point scale for each paw: 0 = no arthritis, 1 =
swelling and redness confined to digits, 2 = minor swelling
and redness spreading from the digits to the distal paw, and 3
= major swelling and redness extending proximally from the
paw. Mice were sacrificed on day 28 after immunization unless
otherwise noted, and spleens were removed for processing of
single-cell suspensions from individual mice. For some analy-
ses, the splenocytes were pooled from mice with similar dis-
ease severity as follows: score of 0 to 2 = mild or no arthritis,
score of 3 to 6 = moderate arthritis, and score of 7 to 12 =
severe arthritis.
Antibodies and flow cytometry
Anti-mouse CD19-allophycocyanin (clone 1D3), anti-mouse
CD3-biotin (145-2C11), anti-mouse CD5-biotin (53-7.3), anti-
mouse FasL-phycoerythrin (anti-mouse FasL-PE) (MFL3), anti-
CD4-PE (H129.19), anti-CD8-fluorescein isothiocyanate
(anti-CD8-FITC) (53-6.7), anti-CD38-FITC (clone 90), strepta-
vidin-PE cychrome 7 conjugate (streptavidin-PECy7), and
Annexin-V-FITC were purchased from BD Biosciences (San
Jose, CA, USA). Propidium iodide (PI) was purchased from
Sigma-Aldrich (St. Louis, MO, USA). Freshly isolated single-
cell suspensions from mouse spleens were stained with puri-
fied FcBlock (2.4G2; BD Biosciences) before being labeled
with anti-mouse CD19-APCs and either anti-CD5-biotin or
anti-CD3-biotin for 30 minutes at 4°C in phosphate-buffered
saline (PBS) containing 0.2% bovine serum albumin and 0.1%
sodium azide. Cells were then washed in PBS and fixed in 1%
paraformaldehyde overnight. Fixation solution was washed
away thoroughly followed by labeling of the CD5-stained
group with streptavidin-PECy7, anti-FasL-PE, and anti-CD38-
FITC. Gating used for CD5+ T and B cells was determinedPage 2 of 12
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fact that CD5 expression on B cells is low in comparison with
T cells. The few CD5hiCD19+ cells on the dot plots that were
excluded by gating are not present in the separated popula-
tions and most likely represent doublets of T and B cells as fur-
ther indicated by higher forward scatter characteristics. The
CD3-biotin-stained group was labeled with streptavidin-
PECy7, anti-CD4-PE, and anti-CD8-FITC. Flow cytometry was
performed on a Cytomics FC 500 flow cytometer (Beckman
Coulter, Fullerton, CA, USA), and cell marker analysis was
done using FlowJo software (TreeStar Inc., Ashland, OR,
USA).
Magnetic bead separation
Single-cell suspensions from pooled spleens of mice with
severe, moderate, or mild arthritis were counted and washed
in manufacturer-suggested buffer prior to labeling with anti-
mouse CD19-coated magnetic microspheres (Miltenyi Biotec,
Auburn, CA, USA). Cells were then passed over magnetized
LS columns with the flow-through being collected as the B
cell-depleted (T cell-enriched, approximately 80% T cells)
fraction and the column retentate collected as the purified B-
cell fraction (purity greater than 98% for all groups as deter-
mined by flow cytometry).
Cell cultures for apoptosis measurements
For comparison of T-cell apoptosis in mice with severe, mod-
erate, and mild arthritis, T cell-enriched fractions of pooled
mouse splenocytes were cultured alone or at a 1:1 ratio with
purified B cells in the absence or presence of 10 μg/mL of a
synthetic peptide of cII, cII259-273, which encompasses the
cII260-267 epitope recognized by the transgene (Peptide Syn-
thesis Facility, University of Michigan). Cells were collected on
day 7 of coculture and analyzed for apoptosis as described
below.
In a separate experiment, B cells were magnetic bead-purified
from DR4 Tg mice that had been immunized 21 days prior with
chicken cII in incomplete Freund's adjuvant (Chondrex). Puri-
fied DR4+ B cells were then cultured with an equal number of
human cartilage glycoprotein-39 (HCgp39)-specific T hybrid-
oma cells that are HLA-DR4-restricted [27,28]. The peptide,
cII259-273 (irrelevant peptide for this hybridoma), was added to
some cocultures as a control, whereas other cocultures con-
tained the cognate HCgp39263-275 peptide (10 μg/mL). Neu-
tralizing antibodies to human MHC class II (clone TDR31.1;
Ancell Corporation, Bayport, MN, USA), mouse IL-10 (clone
JES052A5; R&D Systems, Inc., Minneapolis, MN, USA),
mouse FasL (clone 101626; R&D Systems, Inc.), and a rat
IgG1 antibody (isotype control for anti-IL-10 and anti-FasL)
were added at 10 μg/mL at the beginning of the culture. An
agonist antibody recognizing mouse CD4 (clone GK1.5; eBi-
oscience, Inc., San Diego, CA, USA) was used as a positive
control for T-cell apoptosis. T hybridoma cells were collected
at 48 hours of coculture and analyzed for T-cell apoptosis by
three-color flow cytometry [29]. Cells were stained with anti-
mouse CD4-PE, washed, and labeled with Annexin V-FITC
and PI and then analyzed immediately on a Cytomics FC 500
flow cytometer. Gating was performed on CD4+ and PI- cells
to exclude non-Th cells and cells that were already dead, and
then labeling of Annexin-V-FITC was analyzed using FlowJo
software.
Cell cultures for analysis of cytokine production
Cell-free supernatants were collected on days 2 and 5 from
cultures containing splenocytes (2 × 106 cells/mL) from CFA/
cII immunized TCR Tg mice mixed with 10 μg/mL cII259-273
peptide. In a separate experiment, B cells were magnetic
bead-purified from unimmunized DBA/1 mice and cultured in
wells that had been precoated with an agonistic anti-mouse
CD40 antibody or wells that were uncoated. After 24 hours of
stimulation, cII259-273 peptide (10 μg/mL) was added to some
wells, followed by the addition of neutralizing antibodies
against mouse FasL or IL-10 (10 μg/mL). Splenocytes from
unimmunized cII TCR Tg mice were depleted of CD19+ B cells
by magnetic bead separation and then added to control wells
or wells containing B cells ± antigen. Cell-free culture super-
natants were collected on days 2 and 5 and analyzed by sand-
wich enzyme-linked immunosorbent assay for the presence of
IFNγ (BD Biosciences) and IL-17 (eBioscience, Inc.), respec-
tively, using manufacturer protocols.
Statistical analysis
Linear regression comparisons were performed using Graph-
Pad Prism software (version 3; GraphPad Software, Inc., San
Diego, CA, USA). Student t tests were performed on data sets
in bar graphs and are reported as follows: one symbol indi-
cates P < 0.05; two symbols, P < 0.02; and three symbols, P
< 0.01. Designations for the symbols used for error compari-
sons in individual graphs are listed in the figure legends.
Results
The initial aim of this study was to establish a potent arthritis
model using a TCR Tg strain of mice specific for cII in the con-
text of MHC class II I-Aq (DBA/1 background) [26]. An estab-
lished immunization protocol for collagen-induced arthritis
involving a single injection at the base of the tail of cII in CFA
was used, and joint inflammation was noted for some mice
beginning at day 16 after immunization and showed rapid pro-
gression to severe arthritis for some of the early responders
(Table 1). However, a significant portion of the mice had no
visible inflammation or had only mild arthritis by day 27 after
immunization. Disease scores on day 27 ranged from 0 (non-
arthritic) to 12 (highest possible), with good representation of
all scores in between. Disease activity was independent of
which cage the mice were housed in, and splenocytes from all
mice responded to recall challenge with cII peptide in vitro by
producing IL-17 or IFNγ or both, indicating that all had been
successfully immunized. The broad range of disease activity
suggested that there were individual differences in the immunePage 3 of 12
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by genetic or environmental factors.
Analysis of splenic lymphocyte populations from individual
mice showed that the total number of white cells ranged from
5.5 × 107 to 1.7 × 108 cells per mouse, with a trend (that did
not reach statistical significance) toward fewer total lym-
phocytes in the more severely arthritic mice (Table 1). Lym-
phocyte subset analysis revealed that the relative number of
CD4+/CD3+ T cells, CD8+/CD3+ T cells, and CD5-/CD19+ B
cells was unchanged regardless of disease severity (Figure 1).
However, a statistically significant reduction in CD5+/CD19+
B cells was noted in the spleens correlating to increasing
severity of inflammation (Figure 1).
Mouse CD5+/CD19+ splenocytes were previously shown to
be constitutively positive for expression of FasL and could be
induced to express higher levels of FasL by exposure to anti-
gens and the cytokines IL-4 and IL-10 [23]. Therefore, FasL
expression was analyzed on splenic populations of the individ-
ual mice and compared with disease activity. Splenic lym-
phocytes were first gated on forward scatter and side scatter
(not shown) and then subdivided on the basis of expression of
CD5 and CD19 into four groups (Figure 2a). T cells (both
CD4+ and CD8+) are constitutively high expressers of CD5
and therefore comprise the CD5+/CD19- fraction. CD5+ B
cells have lower expression of CD5 than T cells and were
gated based on control samples that lacked T cells in order to
exclude doublets of T and B cells from the analysis. FasL
expression was highest on the CD5+/CD19+ B-cell subset but
was also detected at a lower intensity on CD5+/CD19- T cells
(Figure 2c, d). FasL expression varied slightly on CD5+ B cells
from individual mice (Figure 2b), but there were no significant
differences in mean fluorescence intensity on CD5+ B cells
between mice with severe, moderate, or mild arthritis (Figure
2d and Table 1). Thus, differences were noted in the total
number and percentage of FasL+ CD5+ 'killer' B lymphocytes
in severely arthritic mice but not in the intensity of FasL
expression.
To determine the relative importance of killer B cells to T-cell
apoptosis, splenocytes from six mice in each severity group
Table 1
Arthritis scores of type II collagen/complete Freund's adjuvant-immunized T-cell receptor transgenic mice and total splenocyte 
counts at day 28
Mousea Cage Day 16b Day 20 Day 23 Day 27 Final score Category Total number of splenocytes
1 1 0,0,0,0 0,0,1,2 3,0,3,3 3,0,3,3 9 Severe 8.00 × 107
3 1 0,0,0,0 0,0,0,1 0,1,0,0 3,3,0,0 6 Moderate 1.66 × 108
4 1 3,0,1,0 3,3,1,1 3,3,3,3 3,3,3,3 12 Severe 8.72 × 107
5 2 0,0,0,0 0,0,0,0 0,0,0,0 0,0,0,0 0 No arthritis 1.47 × 108
6 2 0,0,0,0 0,0,0,0 0,0,0,0 0,0,0,0 0 No arthritis 1.46 × 108
7 3 0,0,0,0 0,3,1,1 0,3,3,3 0,3,3,3 9 Severe 1.05 × 108
8 3 0,2,0,0 1,3,0,0 1,3,0,0 1,3,0,1 5 Moderate 1.66 × 108
9 3 0,0,0,0 0,0,0,0 0,0,0,0 0,0,1,1 2 Mild 1.22 × 108
10 4 0,0,0,0 0,0,0,0 1,2,0,0 0,2,1,2 5 Moderate 1.56 × 108
11 4 0,0,0,0 0,0,0,0 3,0,1,2 3,0,1,3 7 Severe 5.52 × 107
12 5 0,0,0,0 0,0,1,0 0,0,1,0 0,0,1,0 1 Mild 1.25 × 108
13 5 0,0,0,0 0,0,0,0 1,1,0,1 2,1,0,2 5 Moderate 1.18 × 108
14 5 0,0,0,0 0,0,0,0 0,0,0,0 0,0,0,0 0 No arthritis 7.12 × 107
15 6 0,0,0,0 0,0,0,0 0,0,0,1 0,3,1,3 7 Severe 6.72 × 107
16 6 0,0,0,0 0,0,0,0 0,0,0,0 0,0,0,0 0 No arthritis 8.32 × 107
17 6 0,0,0,0 0,0,0,0 0,0,1,0 0,0,3,1 4 Moderate 8.00 × 107
18 7 0,0,0,0 0,0,0,0 1,2,0,1 1,3,1,3 8 Severe 9.68 × 107
19 7 0,0,0,0 0,0,0,0 0,3,0,0 0,3,3,3 9 Severe 6.40 × 107
20 7 0,0,0,0 0,0,1,1 0,0,2,3 0,0,2,3 5 Moderate 8.72 × 107
aMouse #2 was sacrificed at day 20 due to malnourishment, which was believed to be related to a dental abnormality. This mouse had no signs of 
arthritis on day 20. bArthritis disease scoring is based on a 3-point scale for each paw: 0 = no inflammation, 1 = inflammation confined to digits, 2 
= mild swelling of paw, and 3 = severe swelling encompassing paw, ankle, wrist, and/or knee joints. Scores shown for individual dates are in the 
following order: right fore paw, left fore paw, right hind paw, and left hind paw.Page 4 of 12
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were isolated by magnetic bead separation. Cells were then
recombined at a 1:1 ratio in the presence or absence of cog-
nate antigen for 7 days and analyzed for T-cell apoptosis (Fig-
ure 3). Notably, T cells from severely arthritic mice had lower
baseline apoptosis than those from mildly arthritic mice and
were more resistant to the presence of B cells. Despite the
already high baseline T-cell apoptosis observed in the B cell-
depleted culture from mildly arthritic mice, the addition of B
cells from moderately and mildly arthritic mice, but not severely
arthritic mice, induced a significant increase in T-cell apopto-
sis (Figure 3).
Several lines of evidence have suggested that arthritis in
mouse models is mediated through production of IL-17 by
Th17 cells and is negatively regulated by the presence of IFNγ
[6,8,9,30]. To determine whether the balance of these two
cytokines might be shifted in individual mice, unseparated
splenocytes from the immunized TCR Tg mice were cultured
with antigen and tested for the release of cytokines into the
culture supernatants. As noted above, splenocytes from all
mice responded to antigen with production of IL-17 or IFNγ or
both cytokines in these cultures, indicating successful immu-
nization. However, comparison of the optimal production of
IFNγ (day 2) and IL-17 (day 5) revealed a significant increase
in the ratio of IL-17 to IFNγ in relation to increasing disease
severity (Figure 4a).
Relatively little is known about the sensitivity of Th17 cells to
apoptosis, particularly that mediated by killer B cells. As
shown in Figures 4b and 4c, prestimulation of splenic B cells
through CD40 led to a phenotype that was inductive of
cytokines from naïve T cells of TCR Tg mice in the absence of
cognate antigen but highly suppressive of IL-17 when antigen
was present. This suggested that IL-17 production was tightly
regulated by B cells through an antigen-dependent mecha-
nism. Neutralization of FasL, but not IL-10, restored a signifi-
cant proportion of the IL-17 production that was suppressed
in the antigen-dependent coculture (Figure 4b). IFNγ produc-
tion in the same cultures was less dependent on the blockade
of FasL, although reduced IFNγ in the B cell-depleted culture
in which anti-FasL antibody was present suggested that Fas/
FasL interactions may actually stimulate IFNγ in some circum-
stances (Figure 4c).
To further demonstrate the ability of purified B cells to partici-
pate in antigen-specific T-cell death, coculture experiments
were performed using a T-cell hybridoma cell line that recog-
nizes the arthritis-associated peptide from HCgp39, pre-
sented by human HLA-DR4 [27,28]. As shown in Figure 5, T
hybridoma cells by themselves do not undergo apoptosis in
the presence of HCgp39 peptide. However, when purified
splenic B cells from immunized DR4 Tg mice were added to
the culture, antigen-dependent T-cell apoptosis occurred
(control antibody condition). Neutralizing antibodies to MHC
Figure 1
Reduced percentages of CD5+ B lymphocytes in severe arthritis. Type II collagen/complete Freund's adjuvant (cII/CFA)-immunized, cII T-cell recep-
tor transgenic mice (n = 19) were scored for arthritis severity on a 3-point scale for each paw and then euthanized on day 28 after immunization. Sin-
gle-cell suspensions of splenic leukocytes were stained with antibodies as described in Materials and methods and analyzed by four-color flow 
cytometry. Percentages of CD4+ and CD8+ T cells (among CD3+/B220- lymphocytes) and CD5+ and CD5- B cells (among CD19+ lymphocytes) 
within the small nongranular lymphocyte gate were plotted for individual mice versus the final disease score. Only the percentage of CD5+ B cells 
showed a significant decline as disease severity increased (R-squared = 0.4222, F = 11.69, P = 0.0035). Data are from a representative experiment 
of two experiments (n = 37 mice total).Page 5 of 12
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Figure 2
CD5+ B cells express higher levels of Fas ligand (FasL) than other splenic populations. Freshly isolated splenocytes from type II collagen/complete 
Freund's adjuvant (cII/CFA)-immunized, cII T-cell receptor transgenic mice were stained with anti-CD19, anti-CD5, and anti-FasL antibodies as 
described in Materials and methods. (a) Cells were initially gated as small nongranular lymphocytes by forward scatter and side scatter criteria (not 
shown) and then categorized by staining with anti-CD19 and anti-CD5 as T cells (CD5hi/CD19-), CD5+ B cells (CD5+/CD19+), B-2 cells (CD5-/
CD19+), or double-negatives. (b) Comparison of FasL expression on CD5+ B cells from four mice, with representative disease severity scores 
shown in parentheses. Numbers in the box are mean fluorescence intensity (MFI) values of FasL staining on CD5+ B cells from the four mice. (c) His-
tograms and MFI values compared for lymphocyte subsets of two representative mice. (d) Average MFI values of FasL expression on gated splenic 
lymphocytes from mice with severe (n = 6), moderate (n = 6), and mild or no arthritis (n = 6).
Available online http://arthritis-research.com/content/11/4/R128class II or FasL, but not anti-IL-10 or control antibodies, signif-
icantly decreased T-cell apoptosis, indicating that the B cells
killed T cells through an antigen-specific and FasL-dependent
mechanism.
Discussion
Elimination of antigen-specific T cells is a possible approach
to treatment of arthritis and other autoimmune diseases. Previ-
ous studies have shown that FasL+ 'killer' B cells occur natu-
rally in mice and humans and can regulate the immune
response [22]. In the present study, Tg mice carrying a TCR
transgene specific for a cII peptide varied widely in the severity
of joint inflammation following immunization with cII. This
variability suggested that analysis of individual mice could lead
to clues about the mechanisms controlling arthritis severity.
Various trivial explanations of this variability were excluded.
Immunization of all 19 mice shown in Table 1 was performed
on the same day by the same person with one antigen prepa-
ration. All mice showed evidence of successful immunization.
A subsequent experiment with 18 additional mice yielded sim-
ilar results (data not shown). Differences in disease severity
were detected between mice in the same cage and from the
same litter, suggesting that age, genetics, and environmental
factors were not the major determinants of disease severity.
Differences in arthritis severity correlated with a reduction in
the percentage of CD5+/CD19+ splenic B cells but not CD5-
/CD19+ B cells or T cells. The trend toward fewer total lym-
phocytes in the spleens of severely arthritic mice indicates that
the absolute number of CD5+ B cells was also reduced with
increasing arthritis severity. This result supports the hypothe-
sis that CD5+ B cells can regulate the severity of T cell-driven
arthritis and prompted an analysis of the mechanisms by which
this might occur.
Previous studies have shown that splenic CD5+ B cells
expressed FasL and could induce CD4+ T-cell death. In the
present study, CD5+/CD19+ B cells were indeed the highest
expressers of FasL among splenic lymphocytes in all mice. The
mean fluorescence intensity of FasL staining was not signifi-
cantly different on CD5+ B cells from severely arthritic mice
compared with moderately, mildly, or nonarthritic mice. This
result contrasts with previous studies in a highly polarized Th2
system, in which higher expression of FasL on CD5+ B cells
was a mechanism for decreased inflammation [23]. Thus, the
present data suggest that an insufficient number of killer B
cells, rather than a decrease in FasL expression or functional
killer activity by CD5+ B cells, could be responsible for
reduced immune regulation in severely arthritic mice.
To determine whether arthritis severity could be directly linked
to killer function of B cells, coculture experiments were per-
formed in which B cells were first removed from whole splen-
ocyte preparations and then added back with or without
antigen. T cells from severely arthritic mice were resistant to
apoptosis compared with T cells from mice with less severe
arthritis. B cells were capable of inducing T-cell apoptosis in
Figure 3
Antigen-stimulated T-cell death is dependent on disease severity and is mediated by B cellsi t  i  sev rity and is ediated by B cells. CD19+ B cells were depleted from pooled splenic cells 
of severely, moderately, and mildly arthritic mice (see Table 1 for groupings), leaving enriched populations of T cells. B-depleted cells from each 
group were cultured for 7 days with cII257-273 peptide and cocultured with purified B cells (1:1 ratio) from each group. Apoptosis was measured by 
Annexin V-based three-color flow cytometry as described in Materials and methods. Control T-cell apoptosis in parallel cultures without antigen 
ranged from 5.3% to 22.5%, followed a similar pattern between T-cell groups as shown above, was not stimulated by B cells, and was significantly 
lower than antigen-stimulated apoptosis for every combination. Data shown are mean ± standard error for triplicate samples. Statistical comparisons 
by Student t tests within groups are marked as §mild T versus severe T, ¥mild T versus moderate T, and ¶moderate T versus severe T. Comparisons 
of B cell-mediated death are made to the corresponding culture without B cells and are designated with an asterisk. One symbol = P < 0.05, two 
symbols = P < 0.02, three symbols = P < 0.01. AnnV, Annexin V; PI, propidium iodide.Page 7 of 12
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Figure 4
Interleukin-17/interferon-gamma (IL-17/IFNγ) ratio increases with disease severity and dependence on Fas ligand. (a) Single-cell suspensions of 
splenocytes from individual mice were cultured in the presence of 10 μg/mL of cII259-273 peptide. Culture supernatants were collected on days 2 and 
5 and tested for IFNγ and IL-17, respectively, by enzyme-linked immunosorbent assay (ELISA) as described in Materials and methods. The ratio of 
antigen-stimulated IL-17 to IFNγ was determined for each mouse and plotted against the disease score for that mouse. Linear regression was per-
formed using GraphPad Prism software and showed a significant correlation between a higher IL-17/IFNγ ratio as disease severity increased (R-
squared = 0.2539, F = 5.444, P = 0.033). (b-c) Splenic CD19+ B cells were magnetic bead-purified from naïve DBA/1 mice and cultured overnight 
in the presence or absence of plate-bound anti-mouse CD40 antibody. After 24 hours of culture, cII peptide was added to indicated samples, fol-
lowed by the addition of splenocytes from naïve cII T-cell receptor transgenic mice that had been depleted of CD19+ cells by magnetic bead sepa-
ration. Supernatants were collected 5 days after the addition of B-depleted cells, and IL-17 (b) and IFNγ (c) levels were determined by ELISA. Data 
shown are mean ± standard deviation of triplicate samples. Ag, antigen; cII, type II collagen; FasL, Fas ligand.
Available online http://arthritis-research.com/content/11/4/R128an antigen-dependent and disease severity-dependent man-
ner. These data suggested that the relatively small differences
in the number of FasL+ B cells in the cocultures played a sig-
nificant role in directing T-cell death. An implication of these
findings is that interventions that would reduce resistance of T
cells to apoptosis and/or increase the number of FasL+ CD5+
B cells could tip the balance toward regaining immune
tolerance.
The role of CD5+ B cells in RA has been debated for many
years. CD5+ B cells are capable of producing autoreactive
antibodies, including rheumatoid factor (RF) [31-33]. How-
ever, the relative contributions of CD5+ and CD5- B cells to RA
pathogenesis remain elusive [34]. Some of the initial investiga-
tions comparing CD5+ B cells in the circulation of RA patients
and their nonarthritic first-degree relatives did not show signif-
icant differences, whereas other studies found not only signif-
icantly elevated CD5+ B-cell levels in the blood of arthritic
individuals, but also a correlation between the higher number
of CD5+ B cells and higher titers of IgM RF [35-37]. In another
study, the relative number of IgG RF+ CD5+ B cells was
reduced in arthritis patients whereas the number of IgG RF+
CD5- B cells was elevated [38]. Yet more confusing are the
findings that elevated CD5+ B-cell levels in peripheral blood
are associated with both earlier onset of and remission of RA
[39,40]. Perhaps the present findings of FasL expression on
CD5+ B cells and the inverse correlation between total num-
bers of splenic CD5+ B cells and arthritis severity in mice can
shed new light on these apparent contradictions.
If a normal function of CD5+ B cells is to express FasL and reg-
ulate immune reactions through induction of T-cell apoptosis,
then the specificity of CD5+ B cells for autoantigens could be
a mechanism leading to peripheral tolerance of autoreactive T
cells. Uptake of autoantigens by CD5+ B cells and subsequent
presentation to T cells by cells that coexpress FasL would lead
to selective elimination of the autoreactive T cells and protec-
tion from autoimmunity. However, if an individual had a defect
in the number of CD5+ B cells, in the expression of FasL by
CD5+ B cells, or in the T-cell response to death signals, then
this mechanism of peripheral tolerance could be ineffective,
and interaction of CD5+ B cells with T cells might lead to exac-
erbation of disease by increasing the T-cell response to
autoantigens.
Cocultures of naïve T cells with activated B cells in the pres-
ence of antigen and neutralizing antibody to FasL showed that
B cells could preferentially regulate the production of IL-17
versus IFNγ in a FasL-dependent manner. Surprisingly, signifi-
cant production of IL-17 was elicited by coculture of naïve T
cells with anti-CD40-activated purified B cells when antigen
was not present. In contrast to its role in antigen-dependent
interactions, FasL did not appear to be regulating the produc-
tion of IL-17 in the absence of antigen. This suggests that
Figure 5
Peptide-specific and Fas ligand-dependent killing of T hybridoma cells by purified B cellsll . Splenic CD19+ B cells were magnetic bead-purified from 
incomplete Freund's adjuvant/type II collagen (cII)-immunized human major histocompatibility complex (MHC) class II DR4 transgenic mice. Purified 
B cells (> 98% pure) were pulsed with peptides cII259-273 or HCgp39263-275 and then cultured with neutralizing antibodies against human MHC class 
II, mouse interleukin-10 (IL-10), or mouse Fas ligand. An isotype control antibody (rat IgG1) and an agonist anti-mouse CD4 antibody, used as a pos-
itive control for induction of T-cell apoptosis, were added to some wells as controls. One hour after the addition of antibodies, DR4-restricted, gp39-
specific, T hybridoma cells were added at a 1:1 ratio to the original number of B cells. Cells were collected 24 hours later and analyzed for T-cell 
apoptosis by Annexin V-based, three-color flow cytometry. Data shown are mean ± standard deviation of triplicate samples. Ab, antibody; AnnV, 
Annexin V; APC, antigen-presenting cell; DR4, human class II major histocompatibility complex DRB1*0401; PI, propidium iodide.Page 9 of 12
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between T- and B-cell populations that drive Th17 cell activity,
a finding that may have implications concerning the role of acti-
vated B cells interacting with 'bystander' T cells.
Interestingly, blockade of IL-10 in these cocultures had no
effect on the production of IL-17 or IFNγ. Cytokine production
by B cells has received increasing attention over the past sev-
eral years [41-44]. Among the cytokines produced by B cells,
IL-6 and IL-10 are of particular interest because of their
reported production by CD5+ B cells and their respective pro-
and anti-inflammatory effects in arthritis models [45,46]. Intra-
cellular cytokine staining of freshly isolated splenocytes from
immunized cII TCR Tg mice demonstrated that IL-10+ subsets
were found within both CD4+ cells and CD5+ B cells (data not
shown). We found a significant decrease in the percentage of
IL-10+ CD5+ B cells corresponding to increasing disease
severity, which was not evident in the IL-10+ or FoxP3+ Treg
cell subset (data not shown).
The ability of B cells to regulate immune responses through
expression of FasL and induction of cell death of T cells is a
fairly new concept [22]. Although antigen-dependent T-cell
death has been demonstrated using purified CD5+ B cells in
the murine model of Schistosoma mansoni infection [23], the
present report is the first to show that T-cell death could be
stimulated using a peptide derived from an arthritis-associated
autoantigenic peptide. Death induction was highly dependent
on B cells, specific antigen, and MHC and was at least partially
dependent on FasL. This suggests that killer B cells may be an
effective mechanism to target antigen-specific T cells to
undergo apoptosis.
At present, it is unclear whether CD5+ B cells play a similar
role in immune regulation in human patients. FasL expression
has been detected on human B cells in CD5+ B-CLL lines [47]
but has never been directly studied on nonmalignant CD5+ B
cells in humans. Recent studies of B-cell depletion in RA
patients have shown that there are clear therapeutic benefits
to eliminating B cells, presumably by eliminating pathogenic B
cells that may contribute to inflammation through antigen pres-
entation to autoreactive T cells, proinflammatory cytokine pro-
duction, and/or production of autoantibodies [48,49].
Although the present study might seem to contradict the ben-
efit of B-cell depletion therapy, evidence in mouse models sug-
gests that CD5+ B cells may be protected from depletion
mediated by anti-CD20 antibodies, and evidence from the
anti-CD20 antibody trials in humans demonstrates that many
of the earliest B cells that repopulate these patients express
CD5 [50,51]. It will be interesting to determine whether the
repopulating CD5+ B cells also preferentially express FasL
and to study immunoregulatory effects of these cells on human
T lymphocytes.
Conclusions
The present findings suggest a novel regulatory role for CD5+
B cells on disease severity in a murine model of arthritis. The
dependency of B cell-mediated killing on antigen specificity
implies that FasL+ B cells might be useful to eliminate arthri-
togenic T cells specifically, without harming other T cells that
are necessary for defense against infections or neoplasm. If
killer/regulatory B cells are shown to be important in control-
ling arthritic inflammation in humans, attractive new goals in
the treatment of RA could include the enhancement of their
killer activity or stimulation of their repopulation after B-cell
depletion.
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